Company Data

BioXcel Therapeutics Inc.

Ticker
BTAI
Current Price
$2.68 -6.62%
Market Cap
$78.5M
Price Target
Refer to Report
Volume
1.5M
52wk Range
$1.91 - $29.56
Advanced Market Data

Overview

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company which is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, which is a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company’s other product candidates are BXCL502 and BXCL702 which is focused on neurodegeneration and hematological malignancies.

Inbox Intel from Channelchek.

Informed investors make more money. And itโ€™s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
ยฉ 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.